Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

Open access

Abstract

AIMS: patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control. METHODS AND RESULTS: we analysed patients with pre-existing DM (n = 4662), including 1036 patients on insulin, those without DM (n = 13 951), and subgroups based on admission levels of haemoglobin A1c (HbA1c; n = 15 150). In patients with DM, the reduction in the primary composite endpoint (HR: 0.88, 95% CI: 0.76-1.03), all-cause mortality (HR: 0.82, 95% CI: 0.66-1.01), and stent thrombosis (HR: 0.65, 95% CI: 0.36-1.17) with no increase in major bleeding (HR: 0.95, 95% CI: 0.81-1.12) with ticagrelor was consistent with the overall cohort and without significant diabetes status-by-treatment interactions. There was no heterogeneity between patients with or without ongoing insulin treatment. ticagrelor reduced the primary endpoint, all-cause mortality, and stent thrombosis in patients with HbA1c above the median (HR: 0.80, 95% CI: 0.70-0.91; HR: 0.78, 95% CI: 0.65-0.93; and HR: 0.62, 95% CI: 0.39-1.00, respectively) with similar bleeding rates (HR: 0.98, 95% CI: 0.86-1.12). CONCLUSION: ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehq325

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cumulative incidence of (A) the primary composite of cardiovascular death, myocardial infarction and stroke and (B) total mortality and (C) major bleeding in the ticagrelor (solid lines) and clopidogrel (dotted lines) groups in patients with diabetes at baseline (blue lines) and no diabetes (red lines).
Figure 1 Cumulative incidence of (A) the primary composite of cardiovascular death, myocardial infarction and stroke and (B) total mortality and (C) major bleeding in the ticagrelor (solid lines) and clopidogrel (dotted lines) groups in patients with diabetes at baseline (blue lines) and no diabetes (red lines).CC BY-NC · PubMed Central
Figure 2 Cumulative incidence of (A) the primary composite of cardiovascular death, myocardial infarction and stroke and (B) major bleeding in the ticagrelor (solid lines) and clopidogrel (dotted lines) groups in patients with levels of HbA1c at baseline above median of 6% (blue lines) and below median of 6% (red lines).
Figure 2 Cumulative incidence of (A) the primary composite of cardiovascular death, myocardial infarction and stroke and (B) major bleeding in the ticagrelor (solid lines) and clopidogrel (dotted lines) groups in patients with levels of HbA1c at baseline above median of 6% (blue lines) and below median of 6% (red lines).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 446

Metadata

Authors
James, S., Angiolillo, D. J., Cornel, J. H., Erlinge, D., Husted, S., Kontny, F., Maya, J., Nicolau, J. C., Spinar, J., Storey, R. F., Stevens, S. R., & Wallentin, L.
Affiliations
  • Uppsala University (SE)
  • University of Florida (US)
  • Medisch Centrum Alkmaar (NL)
  • Lund University (SE)
  • Aarhus University Hospital (DK)
  • AstraZeneca (United States) (US)
  • University of Sheffield (GB)
  • Duke Clinical Research Institute (US)
Corresponding author
James, Stefan
Venue
European Heart Journal
Published
2010-08-29
Volume
31
Issue
24
Pages
3006-3016
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2131184211
Cited by
446
References
22
Citations by year
2026: 10 · 2025: 13 · 2024: 9 · 2023: 15 · 2022: 32 · 2021: 26 · 2020: 23 · 2019: 24 · 2018: 26 · 2017: 28 · 2016: 36 · 2015: 39 · 2014: 36 · 2013: 44 · 2012: 50
FWCI
28.31
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • European Heart Journal (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Teva Pharmaceutical Industries
  • Medicines Company
  • Eisai
  • NIH Clinical Center
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
ticagrelor, clopidogrel, acute coronary syndrome, diabetes mellitus, glycemic control, HbA1c, insulin therapy, stent thrombosis, all-cause mortality, major bleeding, platelet aggregation inhibition, PLATO trial, antiplatelet therapy, ischemic events, bleeding risk stratification
MeSH terms
Clopidogrel, Ticagrelor, Adenosine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glycated Hemoglobin, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Ticlopidine, Treatment Outcome, Acute Coronary Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehq325
The paper
James, S., Angiolillo, D. J., Cornel, J. H., Erlinge, D., Husted, S., Kontny, F., Maya, J., Nicolau, J. C., Spinar, J., Storey, R. F., Stevens, S. R., & Wallentin, L. (2010). Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehq325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.